Dermatology Drug Development Summit on November 18-20, 2025 in Boston, United States

The Industry’s Destination to Discover and Develop Best-In-Class Drugs for Immuno-Inflammatory Skin Disease.

As the field surges with clinical and commercial momentum, from Sanofi’s continued success with Dupixent, Corvus' promising Phase 1 data on Soquelitinib, and landmark M AND A deals like Gilead’s $1.7B inflammation partnership with LEO Pharma, the 9th Dermatology Drug Development Summit returns to unite 120+ leading experts committed to solving the most pressing R AND D bottlenecks in dermatology drug development.

Join industry leaders this November, to explore disease heterogeneity, novel therapies and MoA, safety and the evolving reg landscape, as well as deep dives into the latest preclinical and clinical findings across rare and common disease (including AD, Psoriasis, HS, Vitiligo, Pemphigus Nodularis, Bullous Pemphigoid, Alopecia Areata).

From bispecifics to oligos, discover the modalities reshaping derma pipelines and hear insights from AbbVie, Sanofi, Takeda, Incyte, Merck, and others across discovery, preclinical, translational, clinical, and medical affairs.

URLs:

Tickets: https://go.evvnt.com/3189197-2?pid=10008

Brochure: https://go.evvnt.com/3189197-3?pid=10008

Time: 9:00 AM - 4:05 PM

Prices:

Conference Only - Drug Developer Pricing: USD 2999.00,

Full Access Pass Conference + Pre-Conference Workshop Day - Drug Developer Pricing: USD 4197.00,

Conference Only - Academic and Research Institute Pricing: USD 2599.00,

Full Access Pass Conference + Pre-Conference Workshop Day - Academic and Research Institute Pricing: USD 3597.00,

Conference Only - Service and Solution Provider Pricing: USD 3799.00,

Full Access Pass Conference + Pre-Conference Workshop Day - Academic and Research Institute Pricing: USD 5197.00

Speakers: Alexa Kimball, Chief Executive Officer and President, Harvard Medical Faculty Physicians, Ana Rossi, Global Senior Medical Director, Immunology, Sanofi, Anna-Lena Spetz, Chief Scientific Officer and Founder, TIRmed Pharma, Cheri Ackerman, Co-Founder and Chief Executive Officer, Concerto Biosciences, Diana Stefani-Hunyady, Senior Medical Director, Global Clinical Development, Inflammation and Autoimmunity, Incyte, Ethan G. Rigel, Managing Partner, Gore Range Capital, Fredrik Frejd, Chief Scientific Officer, Affibody, Ganesh Mugundu, Vice President and Head of Early Clinical Development, Astria Therapeutics, Harald Schnidar, Founder and Chief Executive Officer , SCARLETRED, Ira C. Spector, Chief Executive Officer and Co-Founder, SFA Therapeutics, Iva Igracki, Director, Medical Affairs Europe, Global Medical Lead, Innovative Dermatology Portfolio, Glenmark Pharmaceuticals, Jennifer palacios, Senior Manager, Marketing, Premier Research, Karl Beutner, Chief Executive Officer and Co-Founder , DermBiont, Nidhi Malhotra, Director, Immunology Drug Discovery, Merck, Ofer Toledano, Vice President - Research and Development, Sol Gel Technologies, Ozge Uluckan, Senior Director, Disease Biology, Almirall, Robin Sinha, Chief Business Officer, Quantificare, Samir Mitragotri, Professor of Bioengineeing, Harvard University, Serena Mandla, CSO and Co-Founder, Noa Therapeutics, Shawn Seong, Chief Executive Officer, Shaperon Inc., Shruti Naik, Associate Professor, Icahn School of Medicine, Mount Sinai, Vanessa Morales-Tirado, Principal Research Scientist, AbbVie